Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Belani
Chandra P
CP
Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA. belanicp@msx.upmc.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D011799:Quinazolines; C015482:protein kinase modulator; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors